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Abstract
Background: Mechanically ventilated patients may receive more sedation during the night than during the day,
potentially delaying extubation. We compared nighttime and daytime benzodiazepine and opioid administration in
adult patients enrolled in a multicenter sedation trial comparing protocolized sedation alone or protocolized
sedation combined with daily sedation interruption; and we evaluated whether nighttime and daytime doses were
associated with liberation from mechanical ventilation.
Methods: This is a secondary analysis of a randomized trial which was conducted in 16 North American medical-
surgical ICUs. In all 423 patients, nurses applied a validated sedation scale hourly to titrate benzodiazepine and
opioid infusions to achieve a light level of sedation. Using fentanyl equivalents and midazolam equivalents, we
compared dosages administered during night (19:00 to 07:00) and day (07:00 to 19:00) shifts. Using multivariable
logistic regression we evaluated the association between nighttime and daytime opioid and sedative doses, and
spontaneous breathing trial (SBT) conduct, SBT success, and extubation.
Results: Nighttime benzodiazepine and opioid doses were significantly higher than daytime doses (mean
difference midazolam equivalents 23.3 mg, 95 % CI 12.9, 33.8, p < 0.0001; mean difference fentanyl equivalents 356
mcg, 95 % CI 130, 582, p = 0.0021). Mean Sedation Agitation Scale score was similar between night and day, and
was at target (3.2 vs 3.3, 95 % CI −0.05, 0.02, p = 0.35). Self-reported nurse workload was similar during the night
and day. Patients were more often restrained during day shifts (76.3 % vs 73.7 %, p < 0.0001), and there were more
unintentional device removals during the day compared with night (15.9 % vs 9.1 %, p < 0.0001). Increases in
nighttime drug doses were independently associated with failure to meet SBT screening criteria, SBT failure, and the
decision not to extubate the patient despite successful SBT.
Conclusion: Patients received higher doses of opioids and benzodiazepines at night. Higher nighttime doses were
associated with SBT failure and delayed extubation.
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Background
Analgesia and sedation are a ubiquitous and essential
component of care for critically ill patients. However, deep
sedation is associated with prolonged mechanical ventila-
tion (MV), longer intensive care unit (ICU) stay [1, 2], and
higher mortality [3, 4]. Mechanically ventilated patients
may receive more sedation during the night compared
with the day [5], potentially delaying extubation [6]. Diur-
nal variation in sedation in critically ill patients is import-
ant to elucidate as it may affect weaning from mechanical
ventilation, impair cognition, and worsen sleep [7].
SLEAP was a multicenter trial that randomized mech-
anically ventilated adult patients to protocolized sedation
(PS) alone (control), or protocolized sedation combined
with daily interruption (DI) of sedation [8]. There was
no difference between the two groups in the primary
outcome of time to extubation (hazard ratio (HR) 1.08,
95 % CI 0.86, 1.35, p = 0.52), nor in secondary outcomes
of ICU and hospital length of stay [9]. However, the DI
group received higher doses of opioids and benzodiaze-
pines, potentially reflecting nurse apprehension about pa-
tient discomfort or the risk of adverse events during DI.
The objective of this study was to describe daytime and
nighttime doses of sedatives and opioids, and to identify as-
sociations between these doses and conduct of spontaneous
breathing trials (SBTs), success of SBTs, and extubation, in
patients enrolled in the SLEAP Trial. We hypothesized that
patients received more opioids and sedatives at night than
during the day, regardless of randomization group, and that
higher nighttime doses would be associated with delays in
the extubation process.
Methods
This was a secondary analysis of the multicenter random-
ized SLEAP trial [8]. We included critically ill adults who
were expected to require mechanical ventilation for longer
than 48 hours and were receiving continuous infusions of
opioids and/or benzodiazepines. Patients admitted to the
ICU after cardiac arrest or traumatic brain injury, patients
receiving neuromuscular blockade, or patients without a
commitment to maximal therapy were excluded. The Re-
search Ethics board at each participating site approved the
study, and written informed consent was obtained from
substitute decision makers.
In both study arms the Sedation Agitation Scale (SAS)
or Richmond Agitation Sedation Scale (RASS) were re-
corded hourly, and nurses titrated opioid and sedative
infusions to achieve a target SAS score of 3 to 4, or
RASS score of −3 to 0. In the DI arm nurses interrupted
benzodiazepine and opioid infusions daily; if ongoing
infusions were necessary they were resumed at half the
previous dose(s). If infusions were no longer necessary pa-
tients were managed with intermittent doses of opioids
and sedatives. Mechanical ventilation was weaned at the
discretion of the ICU team. As previously described [2],
patients in both arms were screened daily by respiratory
therapists for eligibility to have an SBT; information about
successful SBTs was communicated to the ICU team with
a view to extubation. Decisions on extubation were at the
discretion of the ICU team.
We recorded total doses of sedatives and opioids
administered to patients during mechanical ventilation, as
infusions and intermittent bolus doses. We calculated
total medication doses and number of bolus doses admin-
istered during night shifts and day shifts. Night shifts were
defined as 12 hours from 19:00 to 07:00 hours, and day
shifts were defined as 12 hours from 07:00 to 19:00 hours.
Twice daily at the end of each shift, bedside nurses re-
corded their perceived additional clinical workload related
to trial procedures, using a 10-point visual analog scale
(VAS), with 1 corresponding to “very easy” and 10 corre-
sponding to “difficult”. Daily, we recorded physical restraint
use and unintentional device removal during each shift.
Statistical analysis
Descriptive data are presented as percentages for categor-
ical data, means with standard deviations for normally dis-
tributed variables, and medians with interquartile ranges
for non-normally distributed variables. For the analysis,
opioid doses were converted to fentanyl equivalents (10
mg morphine = 2 mg hydromorphone = 0.1 mg fentanyl)
and benzodiazepine doses were converted to midazolam
equivalents (1 mg midazolam = 0.5 mg lorazepam) [8].
RASS scores were converted to an SAS equivalent [8]
(Additional file 1, Table 1).
Using multivariable logistic regression with generalized
estimating equations (GEE) to account for repeated mea-
surements within patients, we evaluated the association
between the nighttime and daytime opioid and sedative
doses on the previous study day with three different out-
comes: 1) meeting criteria to have an SBT; 2) passing
the SBT; and 3) not being extubated despite passing the
SBT. The baseline covariates included in our model were
randomization group, age, sex, and medical vs surgical
diagnosis. In order to account for the time-dependent na-
ture of sedative exposure, our model accounted for the
Mehta et al. Critical Care  (2016) 20:233 Page 2 of 7
daytime benzodiazepine dose on the previous study day,
the difference between nighttime and daytime benzodiazep-
ine dose, daytime opioid dose, and difference between
nighttime and daytime opioid dose, for every patient. All
statistical tests were two sided, with a p value <0.05 consid-
ered statistically significant. All statistical analysis was done
using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Among 423 patients enrolled in the SLEAP study, patient
characteristics were similar between the DI and control
groups. The mean APACHE II scores were 24 and 23, re-
spectively (Table 1), 84 % had medical diagnoses and, at
enrollment, patients had been mechanically ventilated for
a median of 2 days.
Nighttime and daytime benzodiazepine and opioid dosing
Among all 423 patients, nighttime benzodiazepine and
opioid doses were significantly higher than daytime
doses (mean difference midazolam equivalents 23.3 mg,
95 % confidence interval (CI) 12.9, 33.8, p < 0.0001; mean
difference fentanyl equivalents 356 mcg, 95 % CI 130, 582,
p = 0.0021) (Fig. 1 and Table 2). Although patients received
more opioid bolus doses during the day than during the
night, there was no difference in the number of benzodi-
azepine bolus doses administered during night and day
shifts.
Nighttime and daytime dosing in the daily interruption
versus control groups
We compared benzodiazepine and opioid doses adminis-
tered to the DI and control groups (Additional file 1,
Table 2). Compared with the control group, the DI group
received higher benzodiazepine doses during both day
(mean difference 9 mg, 95 % CI 0.1, 18.0, p = 0.047) and
night (mean difference 12 mg, 95 % CI 2.7, 21.1, p = 0.01)
shifts, and higher opioid doses during both day (mean dif-
ference 336 mcg, 95 % CI 236, 436, p < 0.0001) and night
(mean difference 405 mcg, 95% CI −48, 1636, p < 0.0001)
shifts. In terms of bolus dosing, the DI group also received
more opioid boluses during both day and night shifts, and
more benzodiazepine boluses at night.
We further compared the total doses (infusion and
bolus) administered during the night and day within
each randomization group (Additional file 1, Table 3). In
the DI group, mean total opioid and benzodiazepine
doses administered per shift were higher at night than
during the day. The control group also received more ben-
zodiazepines and opioids at night than during the day. Pa-
tients in the DI group received more opioid boluses
during the daytime compared with nighttime.
SAS scores, nurse workload, device removal, and use of
physical restraint
Mean reported SAS scores did not differ between night
and day shifts, and were within the target range (3.2 vs 3.3,
respectively, mean difference −0.02, 95 % CI −0.05, 0.02,
p = 0.35) (Table 3). Self-reported nurse workload using
a VAS (score 1–10) was similar during the night and
day (3.9 vs 4.0, mean difference −0.04, 95 % CI −0.05,
0.12, p = 0.38). There were more unintentional device
removals (self-extubation, removal of venous access)
during the day compared with the night (15.9 % vs 9.1 %,
p < 0.0001). The majority of patients (78 %) were re-
strained at least once during the study, more often during
day shifts than during night shifts.
Multivariable analyses
Factors independently associated with a patient meeting
the criteria for an SBT (Table 4) were: lower daytime mid-
azolam dose (odds ratio (OR) 0.9930, 95 % CI 0.9892,
0.9969, p = 0.0004), smaller difference between nighttime
and daytime midazolam dose (OR 0.9938, 95 % CI 0.9896,





n = 214 n = 209
Age, years, median (IQR) 57 (46–70) 60 (49–70)
Female sex, n (%) 93 (44) 92 (44)
Type of admission, n (%)
Medical 175 (82) 179 (86)
Surgical 30 (14) 22 (11)
Trauma 8 (4) 6 (3)
Body mass index, median (IQR) 28.2 (23.8–34.2) 28.6 (25.0–33.2)
APACHE II, median (IQR) 24 (18–28) 23 (19–29)
Mechanical ventilation days,
median (IQR)
2 (1–4) 2 (1–4)
Pre ICU conditions, n (%)
Alcohol use 49 (23.0) 44 (21.2)
Tobacco use 48 (22.5) 40 (19.3)
Any psychiatric condition 42 (19.6) 29 (14.4)
Any neurologic condition 33 (15.4) 36 (17.2)
Respiratory disease 17 (8.0) 26 (12.4)
Renal dysfunction 20 (9.4) 16 (7.7)
Habitual drug use 14 (6.6) 10 (4.8)
Liver disease 12 (5.6) 11 (5.3)
Baseline demographic data for patients randomized to each arm of the SLEAP
study. There were no significant differences between the two groups. Pre ICU
conditions: neurological condition defined as stroke, seizure disorder, dementia,
neuromuscular disease, Parkinson’s disease, or other neurological condition;
psychiatric condition includes depression, bipolar disorder, schizophrenia, anxiety
disorder, or other psychiatric condition; respiratory disease defined as home
oxygen, CO2 retention at baseline, or home ventilation; renal dysfunction defined
as chronic renal failure with creatinine >180 umol/L, or chronic dialysis; habitual
drug use other than tobacco or alcohol; liver disease defined as Child Pugh grade
C or known esophageal varices. IQR interquartile range, APACHE II Acute
Physiology and Chronic Health Evaluation II.
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0.9980, p = 0.0004), and lower daytime fentanyl dose
(OR 0.9402, 95 % CI 0.9071, 0.9746, p = 0.0008).
Passing an SBT (Table 5) was independently associated
with lower daytime fentanyl dose (OR 0.9602, 95 % CI
0.9347, 0.9864, p = 0.003), and a smaller difference be-
tween nighttime and daytime fentanyl dose (OR 0.9729,
95 % CI 0.9524, 0.9937, p = 0.01).
The only factor independently associated with a pa-
tient not being extubated after passing an SBT (Table 6)
was a larger difference between nighttime and daytime
midazolam dose (OR 1.0145, 95 % CI 1.0039, 1.0253,
p = 0.007), with more midazolam given at night than
during the day.
Discussion
In the SLEAP study, mechanically ventilated adult pa-
tients in both arms of the trial received more opioids
and benzodiazepines during the night compared with
Table 2 Nighttime vs daytime benzodiazepine and opioid administration in all 423 patients
Nighttime Daytime Mean Difference (95 % CI) P value
Midazolam equivalents
Total dose/pt (mg)a 547 (2220) 523 (2236) 23.3 (12.9, 33.8) <0.0001
Total dose/pt, infusion (mg) 543 (2216) 519 (2231) 23.8 (13.1, 34.5) <0.0001
Total dose/pt, bolus (mg) 4.0 (16.4) 4.5 (16.4) −0.5 (−1.5, 0.6) 0.37
Number of bolusesb 1.2 (4.0) 1.2 (3.9) 0.02 (−0.2, 0.2) 0.81
Bolus dose (mg) 0.39 (1.4) 0.43 (1.5) −0.04 (−0.1, 0.1) 0.41
Fentanyl equivalents
Total dose/pt (mcg)a 8379 (22754) 8024 (23083) 356 (130, 582) 0.002
Total dose/pt, infusion (mcg) 7846 (22270) 7387 (22539) 459 (236, 682) <0.0001
Total dose/pt, bolus (mcg) 534 (914) 637 (1082) −103 (−150, −55) <0.0001
Number of bolusesb 11.0 (14.8) 12.1 (15.9) −1.2 (−1.8, −0.5) 0.0001
Bolus dose (mcg) 51.4 (71.6) 52.4 (59.9) −1.0 (−6.7, 4.7) 0.73
Benzodiazepine (midazolam equivalents) and opioid (fentanyl equivalents) administration for all patients during night (19:00–07:00 hours) and day (07:00–19:00
hours) shifts. All data are presented as mean (SD). Mean difference is presented for total dose/patient (Total dose/pt), and all routes of administration including
boluses and infusions. aTotal dose received over the duration of the study. bTotal number of boluses received over the duration of the study
Fig. 1 Daily benzodiazepine and opioid doses during night and day shifts. Mean benzodiazepine (midazolam equivalents, mg) and mean opioid
(fentanyl equivalents, mcg) administration for all patients during night (N, blue bars, 19:00–07:00 hours) and day (D, red bars, 07:00–19:00 hours)
shifts. Total dose/patient represents doses received for the duration of the study; Total dose/patient as infusion represents total doses received
through intravenous infusion, excluding bolus doses, for the duration of the study. P < 0.005 for all four comparisons of nighttime versus
daytime doses
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during the day. Increased nocturnal sedation was inde-
pendently associated with failure to meet criteria for an
SBT, failure to pass the SBT, and delayed extubation
after passing an SBT.
Greater daytime patient wakefulness is also suggested
by more unintentional device removals (self-extubation,
removal of venous access) and more use of physical re-
straint during day shifts compared with night shifts. It is
unclear why mechanically ventilated patients who were
enrolled in the SLEAP trial received more sedation at
night. It is unlikely that the higher nighttime doses
reflect more patient distress or agitation, given the simi-
lar mean SAS scores and nurse workload during day and
night shifts, less use of physical restraint at night, and
no increase in adverse events at night. It is possible that
nurses or other clinicians perceived that patients, who
had been kept awake during the day for physiotherapy,
procedures, tests, visits, and weaning, needed additional
medications for adequate overnight rest. It is also pos-
sible that the expectation of conventional sleep and signs
of poor sleep may have prompted nurses to administer
more sedative medications at night. An additional possi-
bility is perceived patient discomfort related to a change
in ventilation settings at night. Finally, the difference be-
tween nighttime and daytime doses may reflect more
Table 3 SAS scores, VAS scores and unintentional device
removal during night and day shifts
Nighttime Daytime P value
SAS score, mean (SD) 3.2 (0.8) 3.3 (0.8) 0.35
SAS score, number of values 49437 49264
Nurse VAS score, mean (SD) 3.9 (1.4) 4.0 (1.4) 0.38
Nurse VAS score, number of values 4179 4471
Patients with physical restraint, n (%) 308 (73.7) 321 (76.3) <0.0001
Shifts with physical restraint, median (IQR) 3 (0,6) 3 (1,7) <0.0001
Unintentional device removal, n (%)
At least one 38 (9.1) 67 (15.9) <0.0001
Central venous catheter 2 (0.5) 5 (1.2) <0.0001
Arterial catheter 10 (2.4) 14 (3.3) <0.0001
Endotracheal tube 7 (1.7) 17 (4.0) <0.0001
Gastric tube 24 (5.7) 35 (8.3) <0.0001
Urinary catheter 6 (1.4) 13 (3.1) <0.0001
Peripheral venous catheter 4 (1.0) 9 (2.1) <0.0001
The Riker Sedation Agitation Scale (SAS) score and nurse visual analog scale
(VAS) score represent workload associated with trial procedures, use of
physical restraint, and unintentional device removal during night and day
shifts. IQR interquartile range
Table 4 Variables associated with the patient meeting criteria
for a spontaneous breathing trial, multivariable analysis
Odds ratio 95 % CI P value
lower upper
Sedation protocol and daily
interruption vs sedation
protocol alone
0.956 0.685 1.332 0.79
Age (10-year increase) 1.013 0.892 1.151 0.84
Gender (male vs female) 1.039 0.734 1.474 0.83
Surgical/trauma vs medical 0.799 0.441 1.446 0.46
Daytime midazolam dose
(1 mg increase)
0.993 0.989 0.997 0.0004
Midazolam: nighttime-daytime
dose (1 mg increase)
0.994 0.989 0.998 0.0004
Daytime fentanyl dose
(100 mcg increase)
0.940 0.907 0.975 0.0008
Fentanyl: nighttime-daytime
dose (100 mcg increase)
0.977 0.938 1.018 0.27
Table 5 Variables associated with the patient passing the
spontaneous breathing trial, multivariable analysis
Odds ratio 95 % CI P value
lower upper
Sedation protocol and daily
interruption vs sedation
protocol alone
1.206 0.828 1.756 0.33
Age (10-year increase) 0.949 0.839 1.075 0.42
Gender (male vs female) 1.030 0.716 1.483 0.87
Surgical/trauma vs medical 1.598 0.884 2.891 0.12
Daytime midazolam dose
(1 mg increase)
0.998 0.994 1.001 0.13
Midazolam: nighttime-daytime
dose (1 mg increase)
0.997 0.992 1.002 0.28
Daytime fentanyl dose
(100 mcg increase)
0.960 0.935 0.986 0.003
Fentanyl: nighttime-daytime
dose (100 mcg increase)
0.973 0.952 0.994 0.01
Table 6 Variables associated with the patient not being
liberated from mechanical ventilation despite passing the
spontaneous breathing trial, multivariable analysis
Odds ratio 95 % CI P value
lower upper
Sedation protocol and daily
interruption vs. sedation
protocol alone
0.957 0.644 1.421 0.83
Age (10-year increase) 1.124 0.987 1.280 0.08
Gender (male vs female) 1.420 0.967 2.086 0.07
Surgical/trauma vs medical 1.066 0.630 1.804 0.81
Daytime midazolam dose
(1 mg increase)
1.008 0.999 1.017 0.07
Midazolam: nighttime-daytime
dose (1 mg increase)
1.014 1.004 1.025 0.007
Daytime fentanyl dose
(100 mcg increase)
1.012 0.961 1.067 0.64
Fentanyl: nighttime-daytime
dose (100 mcg increase)
0.974 0.906 1.047 0.48
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aggressive weaning of sedatives during the day, because
signs of over-sedation were more apparent.
Our finding of increased nocturnal sedation likely re-
flects general clinical practice, given that SLEAP was a
pragmatic trial conducted in 16 centers, and sedation
was managed by bedside ICU nurses. Our observation
contributes to a very small body of literature on diurnal
variation in sedative management and its consequences.
Only three studies, all single-center, have evaluated diur-
nal variation in patient sedation assessment and sedative
administration in critically ill adults. In a prospective
study evaluating the epidemiology of sedative use in 274
mechanically ventilated adults, Weinert et al. found that
daytime nursing staff were more likely to judge patients
as “oversedated” compared to their nighttime counterparts,
despite only small differences in both sedative dosing and
patient behavior [10]. In a study of 140 patients enrolled in
the ABC trial [2] Seymour and colleagues observed that
benzodiazepine and propofol doses were increased at night
on 40 % and 41 % of patient-days, respectively; and an in-
crease in nighttime sedative doses was associated with
failed SBTs, coma and delirium [6]. Pisani and colleagues
examined dosing patterns of fentanyl, lorazepam and halo-
peridol in a cohort of 309 patients 60 years and older, and
found that doses of lorazepam and haloperidol were higher
during the evening shifts (16:00 hours to midnight) than
during the day or night shifts [5].
The strengths of our study include protocolized
sedation management, multicenter representation, hourly
documentation of SAS/RASS and opioid/sedative admin-
istration, and self-reported nursing workload assessment.
Sedation management in the SLEAP study was pragmatic;
the research team did not guide the ICU staff in sedative
practices [11]. “Usual care” was assumed, and may vary to
a significant degree based on prevailing practice patterns
and local culture in different institutions, and the type of
ICU (medical vs surgical). These institutional and patient
variables may contribute to the increased use of sedatives
at night.
Limitations of this study include the observational
design of this secondary analysis, and the possibility
of omitting important covariates. The generalizability
of our findings to shorter-acting sedative agents, such
as dexmedetomidine or propofol, may be limited. Our
results may not apply to patients experiencing drug
withdrawal, which we did not record, or to patients
receiving psychotropic medications, used predominantly
at night, which have sedative properties of their own.
No formal pain scale was used, and sedative/opioid
management was guided by patient assessment and
SAS or RASS. Finally, the similar SAS scores during the
day and night may reflect inaccurate nighttime SAS scor-
ing or reporting by nurses, if they were reluctant to awaken
patients. Another possible explanation is insensitivity of
the mean SAS score to express small but clinically import-
ant differences.
Our findings underscore the need for frequent re-
assessment of the patient’s sedative and analgesic needs,
even during the night. Patients and clinicians would
benefit from further research exploring the diurnal vari-
ation in sedation, including the reasons for increases in
nighttime sedation and barriers to minimizing nighttime
sedation.
Conclusions
Patients enrolled in the SLEAP trial received more opioids
and benzodiazepines at night than during the day. The
reasons for this remain unclear, and factors such as poor
patient sleep, changes in medical personnel, and nighttime
changes in ventilator settings may contribute to diurnal
sedative variation. Increased nocturnal sedation has
important adverse patient consequences, as we found it
was independently associated with delayed extubation.
Our findings highlight the importance of minimizing
sedation at night, as well as during the day.
Key messages
 In the SLEAP trial, a randomized controlled trial
conducted in 16 North American medical-surgical
ICUs, mechanically ventilated adults received higher
doses of benzodiazepines and opioids at night
compared with daytime doses
 Increases in nighttime drug doses were independently
associated with failure to meet spontaneous breathing
trial (SBT) screening criteria, SBT failure, and the
decision not to extubate the patient despite a
successful SBT
Additional file
Additional file 1: Variation in diurnal sedation in mechanically
ventilated patients who are managed with a sedation protocol alone or a
sedation protocol and daily interruption. (DOC 74 kb)
Abbreviations
DI, daily interruption; ICU, intensive care unit; OR, odds ratio; PS, protocolized
sedation; RASS, Richmond Agitation Sedation Scale; SBT, spontaneous
breathing trial; SAS, Sedation Agitation Scale; VAS, visual analogue scale
Acknowledgements
We are grateful to the Canadian Critical Care Trials Group for their key role
in this work. We are indebted to David Williamson B.Pharm, M.Sc., Ph.D for
critical review of this article.
Funding
This research was supported, in part by the Canadian Institutes of Health
Research, and the Mount Sinai Hospital Department of Medicine.
Authors’ contributions
Study concept and design: SM, LB, CK, DF, and RM. Acquisition of data:
SM, MM, LB, PD, KB, MH, JWD, MT, RF, MJ, MS, KO, and DC. Analysis and
Mehta et al. Critical Care  (2016) 20:233 Page 6 of 7
interpretation of data: SM, MM, RM, CK, DF, and DC. Drafting of the
manuscript: SM, MM, LB, CK, and DC. Critical revision of the manuscript for
important intellectual content: all authors. Statistical analysis: RM and DF.
All authors gave final approval for manuscript submission.
Authors’ information
Department of Medicine and Interdepartmental Division of Critical Care,
Mount Sinai Hospital and University of Toronto, Toronto, Ontario (Dr Mehta
and Dr Katsios); Departments of Medicine, Clinical Epidemiology &
Biostatistics, McMaster University, Department of Critical Care, Hamilton
Health Sciences, Hamilton, Ontario (Dr Meade); Department of Pharmacy and
Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario
(Dr Burry); Clinical Epidemiology Program, Ottawa Hospital Research Institute
and Faculty of Medicine, University of Ottawa, Ottawa, Ontario (Drs Mallick
and Fergusson); Division of Critical Care Medicine and Center for Health
Evaluation and Outcome Sciences, St. Paul’s Hospital and University of British
Columbia, Vancouver, British Columbia (Dr Dodek); Keenan Research Centre
and the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto,
Ontario, Interdepartmental Division of Critical Care Medicine and the Institute
of Health Policy Management and Evaluation, University of Toronto, Toronto,
Ontario (Dr Burns); Department of Medicine and Interdepartmental Division
of Critical Care, University Health Network and University of Toronto,
Toronto, Ontario (Dr Herridge); School of Pharmacy, Northeastern University,
Boston, Massachusetts (Dr Devlin); Department of Medicine, Long Beach
Memorial Medical Center, Long Beach, California (Dr Tanios); Departments of
Medicine and Critical Care Medicine, Sunnybrook Hospital, Interdepartmental
Division of Critical Care Medicine, University of Toronto, Toronto, Ontario
(Dr Fowler); Departments of Anesthesiology and Critical Care, University of
Alberta Hospital, Edmonton, Alberta (Dr Jacka); McGill University, Montréal,
Québec (Dr Skrobik); Section of Critical Care, Department of Medicine,
Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba (Dr Olafson);
Departments of Medicine, Clinical Epidemiology & Biostatistics, McMaster
University, St Joseph’s Healthcare, Hamilton, Ontario (Dr Cook).
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Ethics approval was obtained from the Research Ethics Board of the
following institutions: Mount Sinai Hospital, Toronto, Ontario, Canada;
University Health Network, Toronto, Ontario, Canada; St. Michael's Hospital,
Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto,
Ontario, Canada; St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Hamilton
General Hospital, Hamilton, Ontario, Canada; St. Paul's Hospital, Vancouver,
British Columbia, Canada; Walter C. Mackenzie Health Sciences Centre,
Edmonton, Alberta, Canada; Health Sciences Centre, Winnipeg, Manitoba,
Canada; Maisonneuve Rosemount Hospital, Montreal, Quebec, Canada; Royal
Columbian Hospital, New Westminster, British Columbia, Canada; Surrey
Memorial Hospital, Surrey, British Columbia, Canada; Royal Alexandra Hospital,
Edmonton, Alberta, Canada; Tuft’s Medical Centre, Boston, Massachusetts, USA;
Long Beach Memorial Medical Centre, Long Beach, California, USA
Author details
1Department of Medicine and Interdepartmental Division of Critical Care
Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario,
Canada. 2Departments of Medicine, Clinical Epidemiology and Biostatistics,
McMaster University, Hamilton, Ontario, Canada. 3Department of Pharmacy
and Medicine, Mount Sinai Hospital and University of Toronto, Toronto,
Ontario, Canada. 4Clinical Epidemiology Program, Ottawa Hospital Research
Institute and Faculty of Medicine, University of Ottawa, Ottawa, Ontario,
Canada. 5Interdepartmental Division of Critical Care Medicine, University of
Toronto, Toronto, Ontario, Canada. 6Division of Critical Care Medicine and
Center for Health Evaluation and Outcome Sciences, St. Paul’s Hospital and
University of British Columbia, Vancouver, British Columbia, Canada.
7Department of Critical Care, St. Michael’s Hospital, Toronto, Ontario, Canada.
8Li Ka Shing Institute, Toronto, Ontario, Canada. 9Department of Medicine
and Interdepartmental Division of Critical Care Medicine, University Health
Network and University of Toronto, Toronto, Ontario, Canada. 10School of
Pharmacy, Northeastern University, Boston, Massachusetts, USA.
11Department of Medicine, Long Beach Memorial Medical Center, Long
Beach, California, USA. 12Departments of Medicine and Critical Care Medicine,
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 13Department
of Anesthesiology, University of Alberta Hospitals, Edmonton, Alberta,
Canada. 14Department of Medicine, Hôpital Royal Victoria, Montréal, Quebec,
Canada. 15Section of Critical Care, Department of Medicine, University of
Manitoba, Winnipeg, Manitoba, Canada. 16Departments of Medicine, Clinical
Epidemiology & Biostatistics, McMaster University, St Joseph’s Healthcare,
Hamilton, Ontario, Canada. 17Mount Sinai Hospital, Suite 18-216, 600
University Ave., Toronto M5G 1X5, Canada.
Received: 9 May 2016 Accepted: 12 July 2016
References
1. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative
infusions in critically ill patients undergoing mechanical ventilation.
N Engl J Med. 2000;342(20):1471–7.
2. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT,
Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC, Canonico AE,
Light RW, Shintani AK, Thompson JL, Gordon SM, Hall JB, Dittus RS, Bernard
GR, Ely EW. Efficacy and safety of a paired sedation and ventilator weaning
protocol for mechanically ventilated patients in intensive care (Awakening
and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;
371(9607):126–34.
3. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C,
Seppelt IM, Webb S, Weisbrodt L. Sedation Practice in Intensive Care
Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group. Early
intensive care sedation predicts long-term mortality in ventilated critically ill
patients. Am J Respir Crit Care Med. 2012;186(8):724–31.
4. Shehabi Y, Chan L, Kadiman S, Alias A, Ismail WN, Tan MA, Khoo TM, Ali SB,
Saman MA, Shaltut A, Tan CC, Yong CY, Bailey M. Sedation Practice in
Intensive Care Evaluation (SPICE) Study Group investigators. Sedation
depth and long-term mortality in mechanically ventilated critically ill
adults: a prospective longitudinal multicentre cohort study. Intensive
Care Med. 2013;39(5):910–8.
5. Pisani MA, Bramley K, Vest MT, Akgün KM, Araujo KL, Murphy TE. Patterns of
opiate, benzodiazepine, and antipsychotic drug dosing in older patients in
a medical intensive care unit. Am J Crit Care. 2013;22(5):e62–9.
6. Seymour CW, Pandharipande PP, Koestner T, Hudson LD, Thompson JL,
Shintani AK, Ely EW, Girard TD. Diurnal sedative changes during intensive
care: impact on liberation from mechanical ventilation and delirium. Crit
Care Med. 2012;40(10):2788–96.
7. Trompeo AC, Vidi Y, Locane MD, Braghiroli A, Mascia L, Bosma K, Ranieri VM.
Sleep disturbances in the critically ill patients: role of delirium and sedative
agents. Minerva Anestesiol. 2011;77(6):604–12.
8. Mehta S, Burry L, Cook D, Fergusson D, Steinberg M, Granton J, Herridge M,
Ferguson N, Devlin J, Tanios M, Dodek P, Fowler R, Burns K, Jacka M,
Olafson K, Skrobik Y, Hebert P, Sabri E, Meade M. for the SLEAP Investigators
and the Canadian Critical Care Trials Group. Daily sedation interruption in
mechanically ventilated critically ill patients cared for with a sedation
protocol: a randomized controlled trial. JAMA. 2012;308(19):1985–92.
9. Burry L, Rose L, McCullagh I, Ferguson ND, Fergusson D, Mehta S. Daily
sedation interruption versus no daily sedation interruption for critically ill
adult patients requiring invasive mechanical ventilation. Cochrane Database
Syst Rev. 2014;7:CD009176.
10. Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for
mechanically ventilated patients in a medical and surgical intensive care
unit. Crit Care Med. 2007;35(2):393–401.
11. Rose L, Fitzgerald E, Cook D, Kim S, Steinberg M, Devlin JW, Ashley BJ,
Dodek P, Smith O, Poretta K, Lee Y, Burns K, Harvey J, Skrobik Y, Fergusson
D, Meade M, Kraguljac A, Burry L, Mehta S. for the SLEAP Investigators and
the Canadian Critical Care Trials Group. Clinician perspectives on protocols
designed to minimize sedation. J Crit Care. 2015;30(2):348–52.
Mehta et al. Critical Care  (2016) 20:233 Page 7 of 7
